...
机译:E6201,e6201,e6201的抗肿瘤和抗转移疗效,在三阴性乳腺癌的临床前模型中
Univ Texas MD Anderson Canc Ctr Dept Breast Med Oncol Morgan Welch Inflammatory Breast Canc Res;
Univ Texas MD Anderson Canc Ctr Dept Breast Med Oncol Morgan Welch Inflammatory Breast Canc Res;
Univ Texas MD Anderson Canc Ctr Dept Breast Med Oncol Morgan Welch Inflammatory Breast Canc Res;
Univ Texas MD Anderson Canc Ctr Dept Breast Med Oncol Morgan Welch Inflammatory Breast Canc Res;
Univ Texas MD Anderson Canc Ctr Dept Breast Med Oncol Morgan Welch Inflammatory Breast Canc Res;
Univ Texas MD Anderson Canc Ctr Dept Breast Med Oncol Morgan Welch Inflammatory Breast Canc Res;
Spirita Oncol LLC Natick MA USA;
Spirita Oncol LLC Natick MA USA;
Univ Texas MD Anderson Canc Ctr Dept Breast Med Oncol Morgan Welch Inflammatory Breast Canc Res;
Univ Texas MD Anderson Canc Ctr Dept Breast Med Oncol Morgan Welch Inflammatory Breast Canc Res;
E6201; MEK inhibitor; MAPK pathway; Triple-negative breast cancer; Metastasis;
机译:E6201,梅克1抑制剂的抗肿瘤和抗转移疗效,在三重阴性乳腺癌的临床前模型中(Vol 175,PG 339,2019)
机译:Selinexor(KPT-330)在三阴性乳腺癌的临床前模型中显示出抗肿瘤功效
机译:在p53突变的三阴性乳腺癌临床前模型中对极光和血管生成激酶抑制剂ENMD-2076的差异反应的功效和分子机制
机译:光学相干弹性造影作为对实验中三阴性乳腺癌化疗疗效估算的新方法
机译:某些中药在转移性乳腺癌中的抗肿瘤和抗转移作用以及与唑来膦酸盐联用的研究。
机译:Selinexor(KPT-330)在三阴性乳腺癌的临床前模型中显示出抗肿瘤功效
机译:矫正:E6201的抗肿瘤和抗转移效果,梅克1抑制剂,在三阴性乳腺癌的临床前模型中